Zacks: Brokerages Anticipate Omeros Co. (OMER) Will Announce Earnings of -$0.12 Per Share

Brokerages predict that Omeros Co. (NASDAQ:OMER) will report ($0.12) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have provided estimates for Omeros’ earnings, with estimates ranging from ($0.22) to ($0.02). Omeros reported earnings of ($0.53) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 77.4%. The business is expected to report its next quarterly earnings report on Thursday, May 9th.

According to Zacks, analysts expect that Omeros will report full year earnings of ($0.31) per share for the current fiscal year, with EPS estimates ranging from ($0.78) to $0.17. For the next fiscal year, analysts anticipate that the business will post earnings of $0.81 per share, with EPS estimates ranging from ($0.96) to $2.57. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that cover Omeros.

Omeros (NASDAQ:OMER) last released its earnings results on Friday, March 1st. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.37. The company had revenue of $22.02 million for the quarter, compared to analyst estimates of $22.42 million. Omeros’s revenue for the quarter was up 60.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.34) earnings per share.

Several research firms recently commented on OMER. ValuEngine upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research note on Tuesday, January 15th. Zacks Investment Research upgraded shares of Omeros from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Thursday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Omeros in a research note on Monday, March 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company. Omeros presently has a consensus rating of “Buy” and a consensus target price of $27.00.

Several institutional investors have recently made changes to their positions in OMER. JPMorgan Chase & Co. increased its position in shares of Omeros by 65.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,421 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 6,116 shares in the last quarter. BlackRock Inc. increased its position in shares of Omeros by 1.0% during the 3rd quarter. BlackRock Inc. now owns 3,957,936 shares of the biopharmaceutical company’s stock worth $96,614,000 after purchasing an additional 38,349 shares in the last quarter. Allianz Asset Management GmbH increased its position in shares of Omeros by 15.1% during the 3rd quarter. Allianz Asset Management GmbH now owns 73,815 shares of the biopharmaceutical company’s stock worth $1,802,000 after purchasing an additional 9,694 shares in the last quarter. Tocqueville Asset Management L.P. increased its position in shares of Omeros by 24.7% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 23,700 shares of the biopharmaceutical company’s stock worth $579,000 after purchasing an additional 4,700 shares in the last quarter. Finally, Man Group plc acquired a new stake in shares of Omeros during the 3rd quarter worth about $286,000. Institutional investors and hedge funds own 49.28% of the company’s stock.

NASDAQ:OMER traded up $0.23 during trading hours on Thursday, hitting $18.69. 7,533 shares of the company traded hands, compared to its average volume of 477,474. The stock has a market cap of $902.53 million, a P/E ratio of -8.39 and a beta of 3.60. Omeros has a twelve month low of $10.30 and a twelve month high of $27.00.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

See Also: What is a Roth IRA?

Get a free copy of the Zacks research report on Omeros (OMER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit